Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Equity (2016 - 2025)

Enanta Pharmaceuticals' Return on Equity history spans 13 years, with the latest figure at 0.75% for Q4 2025.

  • For Q4 2025, Return on Equity rose 14.0% year-over-year to 0.75%; the TTM value through Dec 2025 reached 0.75%, up 14.0%, while the annual FY2025 figure was 0.85%, 16.0% down from the prior year.
  • Return on Equity reached 0.75% in Q4 2025 per ENTA's latest filing, up from 1.14% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.2% in Q1 2021 to a low of 1.14% in Q3 2025.
  • Average Return on Equity over 5 years is 0.62%, with a median of 0.55% recorded in 2023.
  • The largest YoY upside for Return on Equity was 14bps in 2025 against a maximum downside of -36bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.44% in 2021, then grew by 12bps to 0.39% in 2022, then plummeted by -75bps to 0.68% in 2023, then crashed by -31bps to 0.89% in 2024, then grew by 16bps to 0.75% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Return on Equity are 0.75% (Q4 2025), 1.14% (Q3 2025), and 1.09% (Q2 2025).